Eczema Awareness Monthly – An American Academy of Dermatology Official Licensee
0
  • Eczema
  • Articles
  • Expert Panel
  • Guidelines
  • Studies
  • Systematic Reviews
  • Patient Resources
Eczema Awareness Monthly - An American Academy of Dermatology Official Licensee
0
Eczema Awareness Monthly - An American Academy of Dermatology Official Licensee
  • Eczema
  • Articles
  • Expert Panel
  • Guidelines
  • Studies
  • Systematic Reviews
  • Patient Resources
Advertisement
ArticlesEczema

The Efficacy of Abrocitinib After Dupilumab

Awareness Monthly
Posted by Awareness Monthly

The efficacy and safety of abrocitinib in atopic dermatitis patients after switching from dupilumab was investigated where researchers analyzed data from patients who were initially enrolled in the JADE COMPARE study, comparing dupilumab versus abrocitinib.

Learn more at the American Academy of Dermatology. 

Share on
Share on Facebook Share on Twitter Share on Pinterest Share on Email
Awareness Monthly
Previous Article Abrocitinib, Upadacitinib FDA-Approved for Atopic Dermatitis
Next Article Biologic for Atopic Dermatitis FDA Approved

Leave a Reply

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Advertisement

 

Advertisement

 

You Might Also Enjoy

ArticlesEczema

First Topical JAK Inhibitor for Atopic Dermatitis Receives FDA Approval

ArticlesEczema

Pediatric Atopic Dermatitis: Topical Calcineurin Inhibitors

ArticlesEczema

Atopic Dermatitis and COVID-19 Infection Risk

ArticlesEczema

Biologic for Atopic Dermatitis FDA Approved

Load More
Eczema Awareness Monthly - An American Academy of Dermatology Official Licensee

© 2020-2023 Powered by eHealthcare Solutions | Privacy Policy

×